Who is sponsoring NCT00201721?

NCT00201721 is sponsored by Ohio State University Comprehensive Cancer Center.

What condition does NCT00201721 study?

NCT00201721 studies B-Chronic Lymphocytic Leukemia.

What drugs are being tested in NCT00201721?

Interventions: Pentostatin, Rituximab, Cyclophosphamide.

What is the status of NCT00201721?

NCT00201721 is currently COMPLETED.

Last reviewed 2017-02-06 · How we verify

Phase II Trial of Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

NCT00201721 Phase 2 COMPLETED

This study aims to assess the rate of complete and overall response using rituximab and pentostatin with and without cyclophosphamide, to monitor and assess toxicity of this regimen, and to determine the overall and progression-free survival in CLL patients

Details

Lead sponsor	Ohio State University Comprehensive Cancer Center
Phase	Phase 2
Status	COMPLETED
Enrolment	28
Start date	2002-07
Completion	2006-09

Conditions

B-Chronic Lymphocytic Leukemia

Interventions

Pentostatin
Rituximab
Cyclophosphamide

Primary outcomes

To assess the rate of complete and overall response using rituximab and pentostatin with and without cyclophosphamide. — up to 5 years
For this evaluation, patients will be classified as complete responders if either of the following types of response are documented * CCR (Clinically based complete remission) denotes NED (No Evidence of Disease) based on baseline clinical parameters. * CR denotes CCR and, in bone marrow, no nodules and \<30% lymphocytes.

Countries

United States